Bodal Chemicals Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 30 May 2026 | Chemicals & Petrochemicals | Market Cap: ₹950 Cr

Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently. - Expecting 12%-13% EBITDA margin leading to INR70-80 crores net profit and 7%-8% return on investment. - Growth expected from ramp-up in benzene derivatives and TCCA business volumes in next 3-6 months. - Benzene derivatives currently at 20%-30% utilization, targeting 70%-80% utilization by Q3/Q4 FY26. - TCCA market share expected to improve post-import duty clarity, with production resuming as inventory reduces by Q3/Q4. - Focusing on consolidating existing businesses with limited capex for next 2-3 years, mainly small debottlenecking. - Target to raise caustic soda capacity utilization to 90%-95% in coming quarters. - Export contributes ~22% of revenue; U.S. Company targets revenue of around INR1,900 crores for FY26, with a potential upside or downside of 5%.

From Bodal Chemicals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹79

Market Cap

₹950 Cr

P/E Ratio

13.8

How does Bodal Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare Bodal Chemicals Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 3Margin: Rank 2

View Chemicals & Petrochemicals leaderboard →

Bodal Chemicals Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹588 Cr, net profit ₹32 Cr.

Full financials →

📊 Revenue & Sales Performance

Rank 3

→Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently.
→Expecting 12%-13% EBITDA margin leading to INR70-80 crores net profit and 7%-8% return on investment.
→Growth expected from ramp-up in benzene derivatives and TCCA business volumes in next 3-6 months.
→Benzene derivatives currently at 20%-30% utilization, targeting 70%-80% utilization by Q3/Q4 FY26.
→TCCA market share expected to improve post-import duty clarity, with production resuming as inventory reduces by Q3/Q4.
→Focusing on consolidating existing businesses with limited capex for next 2-3 years, mainly small debottlenecking.
→Target to raise caustic soda capacity utilization to 90%-95% in coming quarters.
→Export contributes ~22% of revenue; U.S. export negligible (~1%).

📈 Profitability & Margins

Rank 2

→Company targets revenue of around INR1,900 crores for FY26, with a potential upside or downside of 5%.
→EBITDA margin guidance is around 11% to 12%, corresponding to an operating income of about INR35 crores per quarter.
→Net profit expected approx. INR70 to 80 crores for next year, implying 7% to 8% return on investment (ROI).
→Two key businesses — benzene derivatives and TCCA — are expected to scale up in 3-6 months, contributing positively to margins and profitability.
→Benzene business revenue expected to reach INR100 crores in FY26, potentially INR300 crores at full capacity next year.
→Capacity utilization targets for chlor-alkali near 90-95% within a few quarters.
→Improved pricing in TCCA anticipated by Q3/Q4 post import duty impact, helping margins further.
→Debt reduction plan ongoing, targeting reduction of INR150-175 crores term debt by year-end, aiding financial health.

See what Bodal Chemicals Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→No major capex planned in the next couple of years; focus is on consolidating and optimizing the current setup.
→Small debottlenecking or Brownfield expansions may happen but will be very limited in scale.
→Strategic land sale of about 8 acres at Rajpura to a large chlorine consumer to develop pipeline chlorine buyers, not a real estate deal but a business collaboration.
→The company has about 62 acres of surplus land for future expansions, ensuring capacity for growth over the next 10-15 years.
→Future growth capex will be considered after achieving a targeted debt-to-EBITDA ratio near 2.5, indicating focus on debt reduction before new investments.
→Emphasis on increasing capacity utilization and improving leverage profile before undertaking major capital investments.

💰 Fundraising & Capital Structure

→Currently, Bodal Chemicals is not targeting any major capex for the next couple of years, focusing instead on consolidating the current setup and improving utilization.
→Small debottlenecking or minor brownfield expansions may occur, but nothing major requiring significant fundraising.
→The company is actively aiming to reduce existing term debt by INR150-175 crores by the end of the current year through scheduled repayments and asset sales.
→Targeted debt-to-EBITDA ratio is near 2.5; only after achieving this leverage profile will the company consider next growth plans.
→There is no explicit mention of new equity fundraising in the transcript.
→The focus is on improving profitability and reducing debt before planning any new fundraising for expansion.

See what Bodal Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

No information

The transcript does not explicitly mention the current or expected order book or pending orders for Bodal Chemicals Limited. However, some relevant insights include: - TCCA production was paused due to inventory build-up but is expected to resume with clarity in future demand, likely by Q3 or Q4 of FY26. - Benzene derivatives business is ramping up, with utilization expected to reach 70-80% by Q4 FY26, indicating growing orders. - Dye Intermediates and Dyestuff divisions are maintaining volume and revenue levels with some challenges in raw material prices. - The company expects growth in turnover to INR1,900-2,100 crores in FY26, supported by existing business and new projects. - No specific figures on order book or pending orders were disclosed during the call.

Key Metrics

0 of 5 growth signals positive in the Q1 FY26 call.

Revenue

Rank 3

Margin

Rank 2

Capex

Fundraise

Order Book

No information

How does Bodal Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Bodal Chemicals Ltd

Rev 3Mar 2

See full Chemicals & Petrochemicals sector rankings

What Bodal Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

ACI (Q1 FY26)
Q1 FY26 standalone EBITDA grew 13% YoY to INR 958 million with 33% margin; consolidated net profit stood at INR 401 million. Key concall takeaways from Archean…
PCBL (Q1 FY26)
Plant closures in Europe/North America may open export opportunities, boosting international sales beyond the current 41% mix. Key concall takeaways from PCBL…
RAIN (Q1 FY26)
Carbon segment capacity utilization is around 68%, with efforts to increase utilization underway. Key concall takeaways from Rain Industries's Q1 FY26 earnings…
Styrenix Performance Materials Ltd (Q1 FY26)
Thailand plant utilization is at 50-55% with potential to increase revenue by 70-80% by ramping up capacity and improving product mix. Key concall takeaways…

Compare:vs Solar Industries India Ltd vs PIDILITIND vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Bodal Chemicals Ltd Q1 FY26 results?

What is Bodal Chemicals Ltd share price analysis?

Bodal Chemicals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 13.8 with a market cap of ₹950 Cr. Investors should review the full earnings analysis for detailed insights.

Is Bodal Chemicals Ltd planning capital expenditure?

No major capex planned in the next couple of years; focus is on consolidating and optimizing the current setup.

Keep Bodal Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.